All News

The growing use of immunotherapy in oncology has confronted many community practice-based oncologists with challenges to implementation, but one advocacy group’s new initiative aims to educate and empower.

I have a daily calendar on my desk with very wise sayings. One that really stood out was by J.C.Watts. “It doesn’t take a lot of strength to hang on. It takes a lot of strength to let go.”

Many survivors face times of worry and anxiety. An upcoming appointment, a scan, a new lump, bump or spot can all be triggers for feeling intense anxiety. Here are three simple tools from a fellow survivor to help cope in those times.

In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.

Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.

Mindfulness and meditation for the masses. What does this mean to those of us with a life-threatening disease?

Even a cancer survivor with an upbeat attitude can experience bittersweet blues sometimes out of the blue. There are ways to learn from this feeling, whatever we call it, and keep on going.

Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.

Can fitness make you physically prepared for a medical detour?

The Food and Drug Administration approved Keytruda for the treatment of patients with metastatic small cell lung cancer.

Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.

A novel imaging test developed at UT Southwestern may help to determine which patients with kidney cancer would benefit from treatment with immunotherapy.

Getting back up matters when cancer knocks you down, but so does pausing for reflection.

Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.

As a cancer survivor, I am always on my toes.

Should patients be given a choice on how they wish to receive bad news? One survivor seems to think so.

While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.

From the 9/11 Victim Compensation Fund to the untimely passing of an inspirational Olympic runner, here’s what is making headlines in the cancer space this week.

The Food and Drug Administration approved Kanjinti, a biosimilar to the US-licensed Herceptin, marking it the fifth of its kind.

An expert discusses the exciting approaches under investigation in mantle cell lymphoma and insight into where future research should focus.

How the company of a puppy provided the right amount of post-trauma comfort to help navigate in a post-cancer world.

The remarks posted by patients with cancer on the Internet can be skewed. Here are four tips to keep in mind when researching your condition and treatment options.

A nine-year breast cancer survivor and five-year melanoma survivor shares her thoughts on cancer survivorship with a side of mid-life crisis.

Like opposing wind fronts my emotions collided, spinning off a funnel of survivor guilt on a day I never thought would come.

The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.

Just as we tell the person that we love enduring cancer that they are not alone, as caregivers, neither are we.

Here are three things I learned to avoid when recovering from cancer treatment.

The FDA has granted an accelerated approval to Polivy for use in combination with bendamustine and Rituxan for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma who have received at least two prior therapies.